Small and large molecule drug development often necessitates distinct analytical methodologies. Agil...
Agilex has extensive experience developing and validating like-binding assays for specific immune-on...
Come to Our EBF Session in Barcelona to Hear how Agilex Can Make Your PK Data SPARCL SPARCL stand...
How do Australia's streamlined regulatory process and global tax incentive apply to your toxicology...
by Holly Stefl, Chief Commercial Officer It is with much enthusiasm that Agilex Biolabs introduce...
by Kurt Sales In the realm of bioanalytical research, immunoassays stand as a cornerstone technol...
by Holly Stefl, Chief Commercial Officer Agilex Biolabs is proud to introduce the West Coast of t...
by Dr. Kurt Sales, Chief Scientific Officer Pharmacokinetics is a key component in a drug develop...
by Dr. Kurt Sales, Chief Scientific Officer In the ever-evolving landscape of pharmaceuticals, ad...
Dr. Kurt Sales Presents Groundbreaking Findings at WRIB Conference Recently Dr. Kurt Sales, the C...
by Kurt Sales The rise of Cell and Gene Therapy products is increasingly becoming more prevalent....
Recent Report Shows Australia Rising to 3rd in Number of Industry-Initiated Phase I Clinical Trials...
"*" indicates required fields
